Overview

Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study

Status:
Completed
Trial end date:
2018-10-25
Target enrollment:
Participant gender:
Summary
To assess the acceptance rate, adherence, acceptability, and continuation of oral pre-exposure prophylaxis (PrEP) among young southern African women.
Phase:
Phase 4
Details
Lead Sponsor:
HIV Prevention Trials Network
Collaborators:
Gilead Sciences
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination